Dataset Information

Analyzing the GHSI puzzle of whether highly developed countries fared worse in COVID-19.

ABSTRACT: Global Health Security Index (GHSI) categories are formulated to assess the capacity of world countries to deal with infectious disease risks. Thus, higher values of these indices were expected to translate to lower COVID-19 severity. However, it turned out to be the opposite, surprisingly suggesting that higher estimated country preparedness to epidemics may lead to higher disease mortality. To address this puzzle, we: (i) use a model-derived measure of COVID-19 severity; (ii) employ a range of statistical learning approaches, including non-parametric machine learning methods; (iii) consider the overall excess mortality, in addition to official COVID-19 fatality counts. Our results suggest that the puzzle is, to a large extent, an artifact of oversimplified data analysis and a consequence of misclassified COVID-19 deaths, combined with the higher median age of the population and earlier epidemics onset in countries with high GHSI scores.

SUBMITTER: Markovic S

PROVIDER: S-EPMC9587258 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Analyzing the GHSI puzzle of whether highly developed countries fared worse in COVID-19.

Markovic Sofija S Salom Igor I Rodic Andjela A Djordjevic Marko M

Scientific reports 20221021 1

Global Health Security Index (GHSI) categories are formulated to assess the capacity of world countries to deal with infectious disease risks. Thus, higher values of these indices were expected to translate to lower COVID-19 severity. However, it turned out to be the opposite, surprisingly suggesting that higher estimated country preparedness to epidemics may lead to higher disease mortality. To address this puzzle, we: (i) use a model-derived measure of COVID-19 severity; (ii) employ a range of ...[more]

PMID: 36271249

Similar Datasets

Project description:In December 2019, WHO was informed with several unknown pneumonia cases and later it was found as highly contagious, transmittable and pathogenic viral infection. The novel coronavirus (nCoV-19) was firstly reported from Wuhan city in China. COVID-19 has raised the concern of the world since its emergence from China. The WHO has declared an ongoing COVID-19 outbreak as a pandemic. Till now 6,057,853 confirmed cases with 371,166 deaths have been reported from approximately 213 countries of the world. The aim of this study is to discuss all the aspects related to recently discovered novel coronavirus. The article, therefore, provides a comprehensive study on the genomic, epidemiological, social, clinical and environmental aspects of SARS-CoV-2. SARS-CoV-2 uses human ACE2 receptor as a ligand to bind and transmit its genome just like the SARS-CoV. The clinical symptoms of SARS-CoV-2 are very non-specific and include fever, sore throat, wheezing, rales, headache and rhinorrhoea with round-glass pulmonary opacifications shadowing in X-ray. Many antiviral drugs show efficacy but only in mild to moderate infection levels. Though efforts on development of SARS-CoV-2 vaccine have been started earlier as soon as the pandemic was emerged, till date no effective drug or vaccine has been validated with significant efficacy against the disease; therefore, there is a dire need to design effective vaccine against SARS-CoV-2. Multiple vaccine candidates are still in evaluation and exploratory stages on different clinical models with potential results on different animals and human models. mRNA-1273, ChAdOx1, Ad5-nCoV, INO-4800, LV-SMENP-DC and pathogen-specific aAPC are the most advanced and potential drug candidates against COVID-19. Recent studies have revealed any attractive vaccine candidates as promising therapeutic agents based on different strategies of vaccines. Here, the rationale of this review was also to provide an overview of the pathogenesis of the virus and summarize the updated potential vaccine candidates against SARS-CoV-2.

Project description:Developing countries can generate effective solutions for today's global health challenges. This paper reviews relevant literature to construct the case for international cooperation, and in particular, developed-developing country partnerships. Standard database and web-based searches were conducted for publications in English between 1990 and 2010. Studies containing full or partial data relating to international cooperation between developed and developing countries were retained for further analysis. Of 227 articles retained through initial screening, 65 were included in the final analysis. The results were two-fold: some articles pointed to intangible benefits accrued by developed country partners, but the majority of information pointed to developing country innovations that can potentially inform health systems in developed countries. This information spanned all six WHO health system components. Ten key health areas where developed countries have the most to learn from the developing world were identified and include, rural health service delivery; skills substitution; decentralisation of management; creative problem-solving; education in communicable disease control; innovation in mobile phone use; low technology simulation training; local product manufacture; health financing; and social entrepreneurship. While there are no guarantees that innovations from developing country experiences can effectively transfer to developed countries, combined developed-developing country learning processes can potentially generate effective solutions for global health systems. However, the global pool of knowledge in this area is virgin and further work needs to be undertaken to advance understanding of health innovation diffusion. Even more urgently, a standardized method for reporting partnership benefits is needed--this is perhaps the single most immediate need in planning for, and realizing, the full potential of international cooperation between developed and developing countries.

Dataset Information

Analyzing the GHSI puzzle of whether highly developed countries fared worse in COVID-19.

Publications

Analyzing the GHSI puzzle of whether highly developed countries fared worse in COVID-19.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets